HOME >> BIOLOGY >> NEWS
UC Davis researchers report new molecule that targets leukemia and lymphoma cells

UC Davis Cancer Center researchers have developed a novel peptide that binds to the surface of leukemia and lymphoma cells with extremely high affinity, specificity and stability, and demonstrates remarkable promise as a tool to help image tumors and deliver anti-cancer drugs. The research is reported in the July issue of Nature Chemical Biology.

"We believe that this peptide has great potential for becoming a new, effective imaging and therapeutic agent for patients with lymphoid cancers," said Kit Lam, professor and chief of hematology and oncology at UC Davis Cancer Center and senior author of the paper.

The peptide named LLP2A by Lam binds to a receptor found on the surface of lymphocytes. In the Nature Chemical Biology paper, Lam reports that LLP2A is attracted specifically to malignant lymphocytes, not healthy ones.

The next step will be to evaluate the binding of LLP2A in a larger number of human lymphoma biopsy samples. If those results are positive, Lam plans to test the peptide as a lymphoma imaging agent in patients. Experiments are already under way at the UC Davis School of Veterinary Medicine to evaluate LLP2A in dogs with naturally occurring non-Hodgkin's lymphoma. In addition, Lam and his colleagues have begun testing the peptide as a drug-delivery vehicle for lymphoma tumors in mice.

LLP2A is intended to work like a monoclonal antibody but a peptide is much smaller than an antibody and has the potential to infiltrate cancer cells more successfully. Monoclonal antibodies, engineered to lock onto a specific target molecule, are used to carry radioactive isotopes or anti-cancer drugs directly to a tumor. Three monoclonal antibodies, rituximab (Rituxan), ibritumomab tiuxetan (Zevalin), and tositumomab (Bexxar), have already been approved by the Food and Drug Administration for the treatment of B-cell lymphoma. These antibodies have drawbacks, however: They bind to healthy lymphocytes along with malignant ones; in addi
'"/>

Contact: Claudia Morain
claudia.morain@ucdmc.ucdavis.edu
916-734-9023
University of California, Davis - Health System
12-Jun-2006


Page: 1 2

Related biology news :

1. UC Davis is partner in new $125 million federal bioenergy research center
2. UC Davis study finds high arsenic levels in herbal kelp supplements
3. UC Davis wins new national center for avian flu research
4. UC Davis researchers use heated nanoprobes to destroy breast cancer cells in mice
5. UC Davis researchers discover key to bodys ability to detect subtle temperature changes
6. APS names UC Davis professor Bodil Schmidt-Nielsen Distinguished Mentor and Scientist
7. UC Davis scientists groundbreaking research: Mate-attracting chemicals
8. UC Davis breast cancer researchers report new insights into ductal carcinoma in situ
9. British cattle give TB to badgers, finds UC Davis expert
10. UC Davis study finds distinct genetic profiles
11. UC Davis researchers move biotechnology closer to replacing electronic pacemakers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/25/2019)... HOUSTON (PRWEB) , ... September 25, 2019 , ... ... firm, is pleased to announce it ranked No. 3094 on Inc. Magazine’s annual ... Modality Solutions reported three-year revenue growth of 120 percent. Based on this growth, ...
(Date:9/25/2019)... ... , ... Deep Science Ventures (DSV), a new paradigm for applied ... of cancer research. , Deep Science Ventures was founded to create a better method ... from the start, both at the industry and biological level. , Through their ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... of 3D porous titanium spinal implants with the expansion of its proprietary Ti3D® ... more than tripling the number of cervical and lumbar instrumentation sets available for ...
Breaking Biology News(10 mins):
(Date:9/24/2019)... ... September 24, 2019 , ... ... and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, ... the development of therapies to treat central nervous system (CNS) disorders, today ...
(Date:9/22/2019)... BEAVERTON, Ore. (PRWEB) , ... September 20, 2019 ... ... the commercial launch of Brain-Derived Neurotrophic Factor (BDNF) testing in serum . ... peripheral nervous systems. BDNF stimulates the growth and differentiation of new neurons in ...
(Date:9/17/2019)... ... , ... Jennifer Hermansky and Fang Xie, Ph.D. , attorneys ... 2019 Rising Stars. Hermansky and Xie, named an Immigration Rising Star and a Life ... practice areas. The list highlights attorneys “whose legal accomplishments transcend their age,” according to ...
(Date:9/11/2019)... ... September 09, 2019 , ... Tunnell Consulting, an organization ... that its president and CEO Maryann Gallivan has been accepted into the Forbes ... Council accepted Gallivan based on the role she and Tunnell Consulting ...
Breaking Biology Technology:
Cached News: